Melanoma: Etiology, treatment, and dental implications

General Dentistry

Volumn 54, Issue 1, 2006, Pages 61-66

  Little, James W ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; ETHNIC GROUP; HEAD AND NECK TUMOR; HUMAN; MELANOMA; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; SUNLIGHT; UNITED STATES;

ETHNIC GROUPS; HEAD AND NECK NEOPLASMS; HUMANS; MELANOMA; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SUNLIGHT; UNITED STATES;

EID: 33144489156     PISSN: 03636771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Cancer Statistics for 2005. American Cancer Society;2005.
2. Carlson JA, Slominski A, Linette GP, Mysliborski J, Hill J, Mihm MC Jr, Ross JS. Malignant melanoma 2003: Predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol 2003;120 Suppl:S101-127.
3. Chiller KG, Washington C, Sober AJ, Koh HK. Cancer of the skin. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine, ed. 16. New York: McGraw-Hill;2005:543-549.
4. O'Hanlon KM, Plolak EF, Kabongo ML, Stevens SR, Rose L, Gyulai RP. Melanoma. Available at: http://www.firstconsult.com /melanoma. Accessed May 13, 2005.
5. Tours CT. Melanoma. Available at: http://home.mdconsult.com /clinicaltours/melanoma. Accessed May 27, 2005.
6. Ulger AF, Sen E, Erekul S, Gonullu U. [Malignant melanoma of the lung: Is it easy to determine its origin?] (article in Spanish) Arch Bronconeumol 2005;41:102-104.
7. Stang A, Streller B, Eisinger B, Jockel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005;96:216-221.
8. Katz EE, Suzue K, Wille MA, Krausz T, Rapp DE, Sokoloff MH. Primary malignant melanoma of the urethra. Urology 2005;65:389.
9. Ferri FF. Ferri's clinical advisor: Instant diagnosis and treatment. St. Louis: Mosby; 2005:505-508.
10. Habif TP. Clinical dermatology: A color guide to diagnosis and therapy, ed. 4. St. Louis: Mosby;2004.
11. Savona MR, Jacobsen MD, James R, Owen MD. Ultraviolet radiation and the risks of cutaneous malignant melanoma and non-melanoma skin cancer: Perceptions and behaviours of Danish and American adolescents. Eur J Cancer Prev 2005;14:57-62.
12. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF. Metaanalysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41:45-60.
13. Levi F, Te VC, Randimbison L, La Vecchia C. Trends in incidence of various morphologies of malignant melanoma in Vaud and Neuchatel, Switzerland. Melanoma Res 2005;15:73-75.
14. Cancer statistics for 2004. American Cancer Society;2004.
15. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: Experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005;15:77-82.
16. Machet L, Nemeth-Normand F, Giraudeau B, Perrinaud A, Tiguemounine J, Ayoub J, Alison D, Vaillant L, Lorette G. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. Br J Dermatol 2005;152:66-70.
17. Kumar R, Alavi A. Clinical applications of fluorodeoxyglucose-Positron emission tomography in the management of malignant melanoma. Curr Opin Oncol 2005;17:154-159.
18. Jimenez RE, Panageas K, Busam KJ, Brady MS. Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma. J Clin Oncol 2005;23: 518-524.
19. Roaten JB, Pearlman N, Gonzalez R, Gonzalez R, McCarter MD. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg 2005;140:85-89.
20. Lin D, Kashani-Sabet M, Singer MI. Role of the head and neck surgeon in sentinel lymph node biopsy for cutaneous head and neck melanoma. Laryngoscope 2005;115: 213-217.
21. Rousseau DL Jr, Gershenwald JE. The new staging system for cutaneous melanoma in the era of lymphatic mapping. Semin Oncol 2004;31:415-425.
22. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
23. Palucka AK, Dhodapkar MV, Paczesny S, Ueno H, Fay J, Banchereau J. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J Immunother 2005;28:158-168.
24. Letsch A, Keilholz U, Fluck M, Nagorsen D, Asemissen AM, Schmittel A, Thiel E, Scheibenbogen C. Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. Int J Cancer 2005;114:936-941.
25. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H, Breiteneder H. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 2005;174:976-982.
26. Vance KW, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 2004;17:318-325.
27. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida I, Simpson MA, McCarthy JB. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 2004;165:881-891.
28. Tas F, Yasasever V, Duranyildiz D, Camlica H, Ustuner Z, Aydiner A, Topuz E. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma. Am J Clin Oncol 2004;27:225-228.
29. Sauane M, Lebedeva IV, Su ZZ, Choo HT, Randolph A, Valerie K, Dent P, Gopalkrishnan RV, Fisher PB. Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory pathways. Cancer Res 2004;64:2988-2993.
30. Martinez-Lorenzo MJ, Anel A, Alava MA, Pineiro A, Naval J, Lasierra P, Larrad L. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 2004;295:315-329.
31. Linette GP, Carlson JA, Slominski A, Mihm MC, Ross JS. Biomarkers in melanoma: Stage III and IV disease. Expert Rev Mol Diagn 2005;5:65-74.
32. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11:107-112.
33. Noonan DM, Severino A, Morini M, Tritarelli A, Manente L, D'Agnano I, Starace G, Baldi A, Lombardi D, Albini A, Felsani A, Paggi MG. In vitro and in vivo tumor growth inhibition by a p16-mimicking peptide in p16INK4A-defective, pRb-positive human melanoma cells. J Cell Physiol 2005;202:922-928.
34. Miller CS. Cancer. In: Little JW, Falace DA, Miller CS, Rhodus NL, eds. Dental management of the medically compromised patient. St. Louis: Mosby;2002:387-417.
35. O'Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer 2005;103:1217-1226.
36. Day TA, Hornig JD, Sharma AK, Brescia F, Gillespie MB, Lathers D. Melanoma of the head and neck. Curr Treat Options Oncol 2005;6:19-30.
37. Gu GM, Epstein JB, Morton TH Jr. Intraoral melanoma: Long-term follow-up and implication for dental clinicians. A case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96:404-413.
38. Patton LL, Brahim JS, Baker AR. Metastatic malignant melanoma of the oral cavity. A retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1994;78:51-56.
39. Regezi JA, Sciubba JJ, Jordan RCK, eds. Oral pathology: Clinical pathologic correlations, ed. 4. Philadelphia: W.B. Saunders; 2003:392-393.
40. Regezi JA, Sciubba JJ, Jordan RCK, eds. Oral pathology: Clinical pathologic correlations, ed. 4. Philadelphia: W.B. Saunders; 2003:129-139.
41. Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005;52:92-100.
42. Umeda M, Shimada K. Primary malignant melanoma of the oral cavity-Its histological classification and treatment. Br J Oral Maxillofac Surg 1994;32:39-47.
43. Lockhart PB. Dental care of the medically complex patient, ed. 5. Edinburgh: Wright; 2004.
44. Scully C. Malignant disease II: Cancer and cancer prevention. In: Scully C, Cawson RA, eds. Medical problems in dentistry, ed. 5. Edinburgh: Elsevier;2005:467-479.